朱博B通过阻断VEGFR2信号通路来抑制血管生成和瘤生长
Pan Zhang1, Xing Lai2, Mao-Hua Zhu2
1Department of Pharmacy, Shanghai University of Medicine & Health Sciences, Shanghai, 201318, China.
Heliyon
|July 24, 2023
概括
朱胺B (JuB) 是传统中医药中的一种化合物,有效抑制瘤血管生成和癌症生长. 这项研究揭示了JuB.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 瘤血管生成对于固体瘤的生长至关重要.
- 朱化物B (JuB) 是一种来自Ziziphus jujuba的三类桑因,具有已知的药理活性.
- 朱伯的抗血管性潜力仍然未被探索.
研究的目的:
- 为了研究Jujuboside B (JuB) 的抗血管效应.
- 阐明JuB抗血管性活性背后的分子机制.
- 在临床前癌症模型中评估JuB的疗效.
主要方法:
- 在体外测试:人类静脉内皮细胞的增殖,迁移和管道形成.
- 在体内测试:小胚胎胆 ?? 膜测试,Matrigel插头测试和结肠直肠癌异种移植模型.
- 西部斑点分析以评估信号通路的激活.
主要成果:
- 在剂量取决的方式,JuB显著抑制了内皮细胞的增殖,迁移和管形成.
- 在结直肠癌异种移植模型中,JuB抑制了体内血管生成,并延迟了瘤生长.
- 朱布降低了VEGFR2和下游激酶 (Akt,FAK,Src,PLCγ1) 的酸化.
结论:
- JuB 具有显著的抗血管性质.
- JuB通过抑制VEGFR2信号通路而起作用.
- 朱布显示出作为抗血管性癌症治疗的治疗剂的潜力.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Mechanism of Angiogenesis
5.6K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.6K
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


